Study Reveals Gap in MASLD-Related Liver Cancer Screening: 26% of Non-Cirrhotic Cases Show Low FIB-4 Scores
核心洞察
A multicenter study across seven international sites reveals that 26% of patients with MASLD (搜索)-related hepatocellular carcinoma (搜索) without cirrhosis (搜索) have low FIB-4 (搜索) scores, potentially missing detection through current screening guidelines.
The research, analyzing 615 patients, found that 38% of MASLD (搜索)-related HCC cases occurred in patients without cirrhosis (搜索), challenging current risk assessment protocols.
Patients with low FIB-4 (搜索) scores showed significantly lower alpha-fetoprotein levels and larger tumor diameters, suggesting potential delays in diagnosis under existing clinical pathways.
A new international study has revealed significant limitations in current screening protocols for hepatocellular carcinoma (搜索) (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (搜索) (MASLD (搜索)), highlighting potential gaps in early detection strategies.
The multicenter research, led by Darren Jun Hao Tan from the Yong Loo Lin School of Medicine at the National University of Singapore, examined 615 patients across seven tertiary healthcare centers in Singapore, India, Australia, Japan, South Korea, and the United States. The study period spanned from January 2008 to August 2023.
Key Study Findings
The research revealed that 38% of patients with MASLD (搜索)-related HCC did not have cirrhosis (搜索), and notably, 26% of these non-cirrhotic cases demonstrated low FIB-4 (搜索) scores. The median FIB-4 score across all participants was 3.90 (IQR 2.42–6.42), with 13% of the total cohort showing low FIB-4 scores.
Patients in the study had a mean age of 71 (±11) years and an average BMI of 27 (±7) kg/m². The findings are particularly significant given that current guidelines from major medical associations recommend using FIB-4 (搜索) as the primary risk stratification tool for MASLD (搜索) patients.
Clinical Implications
The study's findings challenge current screening protocols recommended by leading hepatology organizations. The American Gastroenterology Association (搜索) (AGA), American Association for the Study of Liver Diseases (搜索) (AASLD), and European Association for the Study of the Liver (搜索) (EASL) currently recommend secondary risk assessment only for patients with FIB-4 (搜索) scores of 1.3 or higher.
Patients with low FIB-4 (搜索) scores exhibited distinct clinical characteristics:
- Lower median serum alpha-fetoprotein levels (P = .005)
- Significantly larger median total tumor diameter (P < .001)
- No significant association with type 2 diabetes, male sex, or obesity
Disease Context and Significance
MASLD (搜索) represents a spectrum of conditions ranging from simple steatosis to more severe forms of liver disease. The condition has emerged as the fastest-rising cause of HCC globally, making these findings particularly relevant for current clinical practice.
The study's results suggest that current clinical pathways may need revision to ensure early detection of HCC in MASLD (搜索) patients, particularly those without cirrhosis (搜索). The higher tumor burden observed in patients with low FIB-4 (搜索) scores indicates potential delays in diagnosis under existing screening protocols.